Nigeria Centre for Disease Control (NCDC) has announced the detection of 344 additional cases of COVID-19.
The agency in its update for October 5, 2021, said the new cases were recorded in 18 states and the federal capital territory (FCT).
The states that reported new cases are FCT (79), Lagos (62), Rivers (45), Kaduna (33), Plateau (22), Edo (16), Benue (13), Kano (12), Cross River (11) and Delta (11).
Other states are Anambra (9), Abia (8), Jigawa (7), Bauchi (4), Ekiti (4), Kwara (4), Oyo (2), Akwa Ibom (1) and Nasarawa (1).
The agency said eight deaths were recorded on Tuesday, leaving the total number of fatalities at 2,731.
Also, 308 patients recovered from the infection on Tuesday.
NCDC noted that Tuesday’s data includes 40 discharged cases reported from Plateau for October 4 and 5 2021.
To date, Nigeria has reported 206,623 confirmed cases of COVID-19 with 194,475 recoveries.
In other news, United Nations Children’s Fund (UNICEF) says one in six Nigerian youths developed mental health conditions as a result of restrictions relating to the COVID-19 pandemic.
According to a statement issued on Tuesday, UNICEF said the findings were the result of a survey carried out in 21 countries — including Nigeria.
The statement reads;
Indeed, the pandemic has taken its toll. According to early findings from an international survey conducted by UNICEF and Gallup of children and adults in 21 countries, including Nigeria – which is previewed in The State of the World’s Children 2021 – a median of 1 in 5 young people aged 15–24 surveyed said they often feel depressed or have little interest in doing things.?In Nigeria, 1 in 6 young people aged 15-24 surveyed said they often feel depressed, have little interest in doing things, or are worried, nervous or anxious.
Meanwhile, Johnson & Johnson says it has submitted data to US Food and Drug Administration for emergency use approval of a booster shot of its COVID-19 vaccine in people aged 18 and above.
The drugmaker said the data submitted include a late-stage study which found that a booster administered 56 days after the primary dose provided 94 percent protection against symptomatic COVID-19 and 100 percent protection against severe disease.
